How Johnson & Johnson beat expectations in Q1

The healthcare giant saw a marked recovery from the negative impacts of the COVID-19 pandemic.

| More on:
Covid-19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Johnson & Johnson (NYSE: JNJ) has been in the news quite a bit recently. And not for good reasons. The healthcare giant's COVID-19 vaccine is still on pause in the U.S. due to concerns about rare blood clotting issues. A key facility where the vaccine is manufactured has been temporarily shut down while the U.S. Food and Drug Administration (FDA) conducts an inspection.

However, the company recently saw some good news for a change. Johnson & Johnson announced its first-quarter results before the market opened on Tuesday. Here are the highlights from J&J's Q1 update. 

By the numbers

Johnson & Johnson reported revenue in the first quarter of $22.3 billion, an 8% year-over-year jump. This topped the average analysts' revenue estimate of $22.01 billion.

The company announced Q1 net income of $6.2 billion, or $2.32 per share, based on generally accepted accounting principles (GAAP). J&J's GAAP earnings totaled $5.8 billion, or $2.17 per share, in the prior-year period. 

There was a similar improvement on a non-GAAP basis. Johnson & Johnson posted adjusted net income in the first quarter of $6.9 billion, or $2.59 per share. In the prior-year period, the company's adjusted earnings came in at $6.2 billion, or $2.30 per share. J&J also handily beat the consensus analysts' adjusted earnings estimate of $2.34 per share.

Behind the numbers

The best story for Johnson & Johnson in the first quarter came from its medical devices segment. This business was significantly impacted by COVID-19 in 2020. However, sales for the segment jumped 10.9% to nearly $6.6 billion as the medical device market recovered from the pandemic.

J&J's biggest segment also delivered a solid performance in the first quarter. Pharmaceutical segment revenue rose 9.6% to $12.2 billion. Sales increased 7.4% on an operational basis excluding the net impact of acquisitions and divestitures.

This growth was driven by several drugs with especially fast-rising sales. Multiple myeloma drug Darzalex topped the list with Q1 sales soaring 45.6% year over year to nearly $1.4 billion. Autoimmune disease drugs Stelara and Tremfya also were big winners, with sales jumping 18.1% to $2.1 billion and 41% to $418 million, respectively.

Johnson & Johnson also reported sales for its COVID-19 vaccine for the first time in the first quarter. Even though the vaccine didn't win U.S. Emergency Use Authorization until late February, it still raked in $100 million during the quarter.

The company's consumer health segment generated revenue of $3.5 billion, down 2.3% year over year. However, this year-over-year comparison was especially challenging because of the boost in sales of over-the-counter products in the first quarter of 2020 as the COVID-19 pandemic began.

Looking ahead

Despite the solid Q1 performance, the healthcare stock slipped a little in early trading on Tuesday. Why? Johnson & Johnson's full-year guidance was a little lower than what analysts expected.

The company now projects sales of $90.6 billion to $91.6 billion for full-year 2021. This range is narrower than the company's guidance provided in January of sales between $90.5 billion and $91.7 billion. J&J expects adjusted full-year earnings per share (EPS) will come in between $9.42 and $9.57. In January, its outlook projected adjusted earnings per share of $9.40 to $9.60.

An advisory committee is scheduled to meet on Friday of this week to review data about the rare blood clotting issues linked to J&J's COVID-19 vaccine. It's possible that the company will receive more good news with a recommendation for the resumption of the administration of the vaccine.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Dexus right now?

Before you buy Dexus shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Dexus wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Prediction: This artificial intelligence (AI) stock will be worth $5 trillion in 3 years

Let's take a closer look at the catalysts that could propel this stock toward that valuation.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

This Artificial Intelligence (AI) chipmaker just got a game-changing boost from Amazon, and Nvidia investors should be paying close attention

Amazon just made a notable investment in Nvidia's top rival.

Read more »

Happy man working on his laptop.
International Stock News

A once-in-a-decade opportunity: Here's why I'm buying Alphabet stock like there's no tomorrow

Alphabet's stock rarely gets this cheap, and right now could be a once-in-a-decade opportunity to scoop up shares at a…

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
International Stock News

Is Warren Buffett's Berkshire Hathaway the smartest investment you can make today?

So, with all the uncertainty, is Berkshire Hathaway the smartest investment you can make today?

Read more »

Warren Buffet
International Stock News

7 ways Warren Buffett changed my investing approach

I'm a big fan of Warren Buffett, and have been for many years.

Read more »

iPhone with the logo and the word Google spelt multiple times in the background.
International Stock News

Down 12% this year, should you buy Alphabet stock?

The Google owner is underperforming the Nasdaq Composite, which has rallied in recent weeks.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
International Stock News

Missed out on Apple in 2012? Buying Nvidia stock today could be your second chance

By now, it's clear that artificial intelligence (AI) is the next major technology platform.

Read more »

Robot humanoid using artificial intelligence on a laptop.
International Stock News

3 reasons Amazon stock looks like an incredible bargain right now

Here are three reasons Amazon stock looks like a rare bargain at current levels.

Read more »